SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026
Weighted avg shares (diluted) grows, but more slowly than its trailing trend
Q3 FY2026 weighted avg shares (diluted) of 202.44M shares rose 86.8% year over year, behind the +94.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 7.0% from the prior quarter. Over 3 fiscal years it compounded at +77.8% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +86.8% toward the trailing-twelve-month pace of +94.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 109.05M USD
- Year-over-year change
- +78.2%
- 4-year CAGR
- +62.9%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109.05M | +78.2% |
| FY2024 | 2024-12-31 | 61.2M | +120.3% |
| FY2023 | 2023-12-31 | 27.78M | +43.2% |
| FY2022 | 2022-12-31 | 19.4M | +25.3% |
| FY2021 | 2021-12-31 | 15.48M | — |
Weighted Avg Shares (Diluted) vs competitors
How SLS compares with its peers on the latest reported figures
- SLS's LTM Sep 2026 weighted avg shares (diluted) of 179.3M shares is the 2nd highest of the 11 companies compared; the peer median is 88.95M shares.
- Its year-over-year change of +94.5% is the highest of 11, against a peer median of +11.2%.
- Over three fiscal years its annual growth of +77.8% compares with a peer median of +18.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | 205.31M | +3.9% | -3.6% | |
| LTM Sep 2026 | 179.3M | +94.5% | +77.8% | |
| LTM Aug 2026 | 108.1M | +31.0% | +21.3% | |
| LTM Sep 2026 | 106.83M | +34.8% | +93.1% | |
| LTM Mar 2026 | 96.61M | +38.1% | +19.3% | |
AAPGAscentage Pharma Group International | FY2025 | 89.03M | +17.9% | +75.5% |
| LTM Mar 2026 | 88.86M | +4.6% | +28.8% | |
| LTM Mar 2026 | 74.4M | -1.9% | +17.6% | |
| LTM Mar 2026 | 63.26M | +0.8% | +0.9% | |
| LTM Mar 2026 | 40.11M | +19.2% | +4.7% | |
| LTM Mar 2026 | 17.74M | -57.8% | -41.7% | |
| Peer median (excluding SLS) | 88.95M | +11.2% | +18.4% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.6M | 1M | 0 | 0 | 0 |
| Cost of Revenue | 200K | 100K | 0 | 0 | 0 |
| Gross Profit | 7.4M | 900K | 0 | 0 | 0 |
| Gross Margin | 97.4% | 90.0% | — | — | — |
| Research & Development | 21.37M | 30.27M | 24.01M | 19.1M | 16.02M |
| Selling, General & Admin | 11.32M | 12.58M | 13.86M | 12.42M | 12.25M |
| Operating Expenses | 32.69M | 42.85M | 37.87M | 31.51M | 28.27M |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| EBITDA | (18.32M) | (31.49M) | 529K | 632K | (26.86M) |
| EBITDA Margin | -241.1% | -3149.3% | — | — | — |
| Operating Income | (25.29M) | (41.95M) | (37.87M) | (31.51M) | (28.27M) |
| Operating Margin | -332.8% | -4195.0% | — | — | — |
| Interest Income | 6K | 317K | 525K | 632K | 1.41M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.36M | 649K | 529K | 632K | 1.41M |
| Income Before Tax | (20.94M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Pre-Tax Margin | -275.5% | -4130.1% | — | — | — |
| Income Tax Expense | (237K) | 0 | 0 | 0 | 0 |
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Net Margin | -272.4% | -4130.1% | — | — | — |
| EPS (Basic) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| EPS (Diluted) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| Weighted Avg Shares | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
| Weighted Avg Shares (Diluted) | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.